Loading
Vaccine Development / Vaccine / Lyme Disease · Journal article
Virulence · June 22, 2026
A consensus or society position rather than new primary data.
This narrative review systematically summarizes Lyme disease vaccine platforms including whole-cell, subunit, nucleic acid, vector, epitope-based, and anti-microbiota approaches, proposing a triangular strategy integrating antigen multivalency, platform personalization, and geographical customization. The authors identify that achieving balance between broad-spectrum protection and durable immunity remains a critical bottleneck in vaccine development.
Journal article. High-risk populations including outdoor workers, children, and elderly in or traveling to endemic regions in North America and Eurasia.
Lyme disease occurs in more than 70 countries and regions worldwide with approximately 700,000 cases annually in endemic areas A subset of patients experience persistent symptoms for 6 months despite standard antibiotic protocols, defined as post-treatment Lyme disease syndrome (PTLDS) No vaccine candidates have yet overcome all scientific and practical hurdles, though several have entered clinical trials in recent years
Truncated text lacks detailed efficacy or safety data from specific vaccine trials No quantitative comparison of immunogenicity, cost, or safety profiles across platforms
Clinicians should understand that while multiple vaccine platforms are under development, none currently provides broadly protective, durable immunity. The review framework may inform future vaccine selection and patient counseling as candidates advance through clinical development.
Narrative review synthesizing current Lyme disease vaccine development platforms and proposing strategic directions without presenting original clinical or experimental data.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should understand that while multiple vaccine platforms are under development, none currently provides broadly protective, durable immunity. The review framework may inform future vaccine selection and patient counseling as candidates advance through clinical development.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Lyme disease (LD) represents a significant public health challenge in North America and Eurasia. The persistent increase in its incidence may create an opportunity for vaccines to gain broader acceptance. Recent years have seen notable advances in vaccine development. However, achieving a balance between broad-spectrum protection and durable immunity remains a critical bottleneck. This article is presented as a narrative review that systematically summarizes recent progress in Lyme disease vaccine research worldwide, with particular emphasis on the strengths and limitations of approved and investigational candidates. Unlike existing reviews, this study integrates recent clinical investigations of multivalent vaccine candidates with breakthrough advances across diverse vaccine platforms, yielding a comprehensive and current synthesis. We identify critical challenges in contemporary vaccine development and propose actionable solutions. Our forward-looking perspective centers on a triangular strategy that integrates antigen multivalency, platform personalization, and geographical customization, providing a conceptual framework to guide future LD immunoprophylaxis research.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.